SecBot SecBot
SECBOTREPLAY Home › Report › NKTX

NKTX · NKX019 data in myositis, SSc

Nkarta, Inc. · 8-K filed Nov 9, 2026 at 09:20 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 09:20 ET

Nkarta reported initial Phase 1/2 clinical data for NKX019, an allogeneic CAR NK cell therapy, in myositis and systemic sclerosis at ACR Convergence 2026. At the 4 billion cells per dose level, 83% of myositis patients and 86% of systemic sclerosis patients achieved clinically meaningful responses, with a favorable safety profile (no CRS, ICANS, or GvHD in 40 patients). The company plans FDA interactions for registrational pathways and expects additional data in 1H 2027.

  • In myositis, 5/6 (83%) patients at 4B cells/dose with >=3 months follow-up achieved moderate or major TIS responses.
  • In systemic sclerosis, 6/7 (86%) patients at 4B cells/dose achieved rCRISS-25 or greater by Day 90; 5/7 (71%) achieved rCRISS-50 or greater.
  • Median mRSS reduction of 15 points at Day 90 in SSc; 5/7 (71%) achieved >=50% reduction from baseline.
  • No deaths, no treatment discontinuations due to AEs, no CRS, ICANS, IEC-HS, or GvHD among 40 patients across five indications.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access